Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma.

× No keyword cloud information.

6 in total

Review 1. Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies.

Authors: Kristina Ihrmark Lundberg; Diana Treis; John Inge Johnsen
Journal: Curr Oncol Rep Date: 2022-04-01 Impact factor: 5.945

Review 2. Targeting anaplastic lymphoma kinase in neuroblastoma.

Authors: Ganesh Umapathy; Patricia Mendoza-Garcia; Bengt Hallberg; Ruth H Palmer
Journal: APMIS Date: 2019-04-03 Impact factor: 3.205

3. Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.

Authors: Diana Cervantes-Madrid; Joanna Szydzik; Dan Emil Lind; Marcus Borenäs; Mats Bemark; Jean Cui; Ruth Helen Palmer; Bengt Hallberg
Journal: Sci Rep Date: 2019-12-18 Impact factor: 4.379

Review 4. Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.

Authors: Roberto Ciaccio; Piergiuseppe De Rosa; Sara Aloisi; Marta Viggiano; Leonardo Cimadom; Suleman Khan Zadran; Giovanni Perini; Giorgio Milazzo
Journal: Int J Mol Sci Date: 2021-11-28 Impact factor: 5.923

Review 5. Targeting MYCN and ALK in resistant and relapsing neuroblastoma.

Authors: Elizabeth R Tucker; Evon Poon; Louis Chesler
Journal: Cancer Drug Resist Date: 2019-09-19

6. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.

Authors: Tingting Liu; Matthew D Merguerian; Steven P Rowe; Christine A Pratilas; Allen R Chen; Brian H Ladle
Journal: Cold Spring Harb Mol Case Stud Date: 2021-08-02

6 in total